Minerva Neurosciences | NERV - تكلفة المبيعات





تكلفة المبيعات تغيير تاريخ
Acadia Pharmaceuticals USD 28.32M 3.52M 2026-06
Adma Biologics USD 33.74M 16.65M 2026-03
ALKERMES USD 120.7M 47.44M 2026-06
AstraZeneca USD 2.52B 2.73B 2026-06
BioCryst Pharmaceuticals USD 3.84M 5.68M 2026-06
Bristol-Myers Squibb USD 7.89B 4.03B 2026-06
Cipla INR 29.71B 3.4B 2026-06
Clal Biotechnology ILS 16.49M 2.64M 2022-06
Compugen USD 1.82M 1.71M 2026-03
CSL USD 3.87B 2.08B 2025-12
Eli Lilly USD 3.27B 309M 2026-06
GlaxoSmithKline GBP 2.07B 192M 2026-06
Grifols EUR 1.51B 184.45M 2025-12
Halozyme Therapeutics USD 108.68M 67K 2026-06
Ionis Pharmaceuticals USD 2.74M 261K 2026-06
J&J USD 8B 67M 2026-06
Merck USD 3.14B 200M 2026-06
Minerva Neurosciences 386K 31K 2024-06
Neurocrine Biosciences USD 39.4M 25.6M 2026-06
Novartis USD 3.71B 251M 2026-06
Novavax USD 22.1M 608K 2025-12
Pfizer USD 4.09B 498M 2026-06
Roche Holding CHF 7.85B 630M 2026-06
Sanofi EUR 3.02B 656M 2026-06
Takeda JPY 517.6B 42.94B 2026-06
Vanda Pharmaceuticals USD 198.77M 151.12M 2024-12